Notice Number: NOT-DA-18-027
Key DatesRelease Date : August 07, 2018
National Institute on Drug Abuse (NIDA)
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The National Institute on Drug Abuse (NIDA) and various Institute and Center members of the NIH Pain Consortium intend to reissue PA-18-465 Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional) to encourage applications support projects examining the therapeutic potential of cannabinoids and endocannabinoid system across a variety of pain conditions. Research supported under this FOA is wide-ranging. In general, the goal is to understand the role of cannabinoids in the management of chronic pain, in part, to help mitigate the high rate of use and abuse of opioids.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.
The FOA is expected to be published in September 2018 with an expected application due date in October 2018.
This FOA will utilize the R01 activity code.
Details of the planned FOA are provided below.
Research Initiative Details
This Notice encourages investigators to study cannabis-related compounds as alternative therapies for pain management. Important in this endeavor is to develop a deeper understanding of the role of natural cannabinoids and endocannabinoids in pain perception, processes, and outcomes. Research is also needed to determine how to modulate key endocannabinoid receptors, ligands, and enzyme levels in pain conditions. This FOA encourages research project grant (R01) applications that study cannabinoids (phytocannabinoids and synthetic cannabinoids) and the endocannabinoid system to evaluate the therapeutic potential of the endocannabinoid system across a variety of pain conditions.
NCCIH: The role of naturally occurring phytocannabinoids and their derivatives either alone or in conjunction with other complementary approaches (e.g. other natural products, mind-body programs) in modulating the biological and neural systems associated with pain perception and analgesia in relevant model organisms or human subjects as well as the mechanisms underlying cannabinoid analgesic and anti-inflammatory properties. NCCIH will not fund research proposing efficacy or effectiveness clinical trials through this FOA (please see NCCIH Clinical Trial Funding Opportunities instead). Investigators are strongly encouraged to discuss their research plans with NCCIH program staff prior to submitting their application.
Estimated Total Funding TBD
Expected Number of Awards TBD
Estimated Award Ceiling TBD
Primary CFDA Numbers 93.279, 93.213, 93.273, 93.865
Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education)
For-Profit Organization (Other than Small Business)
Indian/Native American Tribal Government (Federally Recognized)
City or township governments
Special district governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Please direct all inquiries to: